Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16920238 | 0.88 | MEN1 (0.33) | MEN1KMT2AKDM4E | |
| SCHEMBL22276407 | 0.85 | MEN1 (0.35) | MEN1KMT2ABLMPMP22HSD17B10 | |
| SCHEMBL13007956 | 0.85 | MEN1 (0.31) | MEN1KMT2AKDM4E | |
| SCHEMBL14980587 | 0.84 | KMT2A (0.47) | MEN1KMT2AADRB2KDM4EALDH1A1 | |
| SCHEMBL14980564 | 0.84 | HSD17B10 (0.41) | MEN1KMT2AKDM4EBLMPMP22 | |
| SCHEMBL20438708 | 0.82 | HSD17B10 (0.38) | MEN1KMT2AKDM4ETDP1BLM | |
| SCHEMBL14193385 | 0.82 | ADRB2 (0.45) | MEN1KMT2AADRB2KDM4EALDH1A1 | |
| SCHEMBL2536610 | 0.80 | KMT2A (0.34) | MEN1KMT2AADRB2KDM4EALDH1A1 | |
| SCHEMBL23181244 | 0.79 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL19419441 | 0.79 | L3MBTL1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338623-A1 | MEDICAL DEVICE COATINGS WITH MICROCRYSTALLINE ACTIVE AGENTS | BANK OF MONTREAL, AS COLLATERAL AGENT | 2023-10-26 | — | — | US | disclosed |
| US-20230338623-A1 | MEDICAL DEVICE COATINGS WITH MICROCRYSTALLINE ACTIVE AGENTS | BANK OF MONTREAL, AS COLLATERAL AGENT | 2023-10-26 | — | — | US | disclosed |
| US-20230338622-A1 | DELIVERY OF HYDROPHOBIC ACTIVE AGENT PARTICLES | BANK OF MONTREAL, AS COLLATERAL AGENT | 2023-10-26 | — | — | US | disclosed |
| US-11529440-B2 | Delivery of hydrophobic active agent particles | SURMODICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11246963-B2 | Compositions and methods for delivery of hydrophobic active agents | SURMODICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11123459-B2 | Hydrophobic active agent particle coatings and methods for treatment | SURMODICS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200237971-A1 | DELIVERY OF HYDROPHOBIC ACTIVE AGENT PARTICLES | BANK OF MONTREAL, AS COLLATERAL AGENT | 2020-07-30 | — | — | US | disclosed |
| US-10617793-B2 | Delivery of hydrophobic active agent particles | SURMODICS, INC. (US) | 2020-04-14 | — | — | US | disclosed |
| WO-2018112196-A1 | HYDROPHOBIC ACTIVE AGENT PARTICLE COATINGS AND METHODS FOR TREATMENT | SURMODICS, INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20180169305-A1 | HYDROPHOBIC ACTIVE AGENT PARTICLE COATINGS AND METHODS FOR TREATMENT | BANK OF MONTREAL, AS COLLATERAL AGENT | 2018-06-21 | — | — | US | disclosed |
| US-9757497-B2 | Delivery of coated hydrophobic active agent particles | SURMODICS, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170204075-A1 | AMINOALCOHOL LIPIDOIDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170112973-A1 | DELIVERY OF HYDROPHOBIC ACTIVE AGENT PARTICLES | BANK OF MONTREAL, AS COLLATERAL AGENT | 2017-04-27 | — | — | US | disclosed |
| US-20170072057-A1 | COMPOSITION AND METHOD FOR DELIVERY OF HYDROPHOBIC ACTIVE AGENTS | BANK OF MONTREAL, AS COLLATERAL AGENT | 2017-03-16 | — | — | US | disclosed |
| US-9555119-B2 | Composition and method for delivery of hydrophobic active agents | SURMODICS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556110-B2 | Aminoalcohol lipidoids and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-01-31 | — | — | US | disclosed |
| US-20150203439-A1 | AMINOALCOHOL LIPIDOIDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2015-07-23 | — | — | US | disclosed |
| US-8969353-B2 | Aminoalcohol lipidoids and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-03-03 | — | — | US | disclosed |
| US-8450298-B2 | Aminoalcohol lipidoids and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110293703-A1 | AMINOALCOHOL LIPIDOIDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338622-A1 | DELIVERY OF HYDROPHOBIC ACTIVE AGENT PARTICLES | AHR, KRT18, CD44 | MEN1 4701/4885KMT2A 164/4885ADRB2 2085/4885 |
| US-20150203439-A1 | AMINOALCOHOL LIPIDOIDS AND USES THEREOF | PHOSPHO1, PNMT, AASDHPPT | MEN1 2403/4885KMT2A 1576/4885ADRB2 1274/4885 |
| US-20200237971-A1 | DELIVERY OF HYDROPHOBIC ACTIVE AGENT PARTICLES | AHR, KRT18, CD44 | MEN1 4701/4885KMT2A 164/4885ADRB2 2085/4885 |
| US-10617793-B2 | Delivery of hydrophobic active agent particles | AHR, KRT18, CD44 | MEN1 4701/4885KMT2A 164/4885ADRB2 2085/4885 |
| US-20110293703-A1 | AMINOALCOHOL LIPIDOIDS AND USES THEREOF | PHOSPHO1, PNMT, AASDHPPT | MEN1 2403/4885KMT2A 1576/4885ADRB2 1274/4885 |
| US-11529440-B2 | Delivery of hydrophobic active agent particles | AHR, KRT18, CD44 | MEN1 4701/4885KMT2A 164/4885ADRB2 2085/4885 |
| US-20170204075-A1 | AMINOALCOHOL LIPIDOIDS AND USES THEREOF | PHOSPHO1, PNMT, AASDHPPT | MEN1 2403/4885KMT2A 1576/4885ADRB2 1274/4885 |
| US-20170072057-A1 | COMPOSITION AND METHOD FOR DELIVERY OF HYDROPHOBIC ACTIVE AGENTS | LIPA, PAICS, PHOSPHO1 | MEN1 2538/4885KMT2A 1550/4885ADRB2 4676/4885 |
| US-11246963-B2 | Compositions and methods for delivery of hydrophobic active agents | PAICS, HNRNPA1, INCENP | MEN1 3599/4885KMT2A 331/4885ADRB2 4469/4885 |
| US-20170112973-A1 | DELIVERY OF HYDROPHOBIC ACTIVE AGENT PARTICLES | AHR, KRT18, CD44 | MEN1 4701/4885KMT2A 164/4885ADRB2 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.